FB7023 / Frontier Biotech - LARVOL DELTA

FS.09: Featured Science: Lp(a) (AHA 2026) - "Optimization of Atherogenic Lipid Management With RN5681, a Bivalent SiRNA Targeting PCSK9 and Lp(a) FB7023, a Novel Dual-Targeting siRNA Against PCSK9 and Lpa, Simultaneously Reduces Both LDL-C and Lp(a), Exhibiting High-Value Treatment Potential for Management of ASCVD Prospective In Silico Prediction of the Lp(a) HORIZON Trial Using a Mechanistic Atherosclerotic Cardiovascular Disease Model Frenchie Lpa - Variability of Lipoprotein(a) Measurement Between Acute Myocardial Infarction at Admission, Discharge and Follow Up"

Late-breaking abstract • Atherosclerosis • Cardiovascular • Myocardial Infarction

FB7023, a Novel Dual-Targeting siRNA Against PCSK9 and Lpa, Simultaneously Reduces Both LDL-C and Lp(a), Exhibiting High-Value Treatment Potential for Management of ASCVD (AHA 2026) - No abstract available

Late-breaking abstract • Cardiovascular